Cargando…

Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study

PURPOSE: To estimate the number of sick leave days and productivity costs in active workers with osteoarthritis (OA) who initiated opioid treatment for moderate/severe chronic pain in clinical practice in Spain. PATIENTS AND METHODS: This is a secondary analysis of the longitudinal, retrospective OP...

Descripción completa

Detalles Bibliográficos
Autores principales: Sicras-Mainar, Antoni, Tornero-Tornero, Juan Carlos, Vargas-Negrín, Francisco, Lizarraga, Isabel, Sicras-Navarro, Aram, Rejas-Gutierrez, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8937618/
https://www.ncbi.nlm.nih.gov/pubmed/35321217
http://dx.doi.org/10.2147/OARRR.S346746
_version_ 1784672382751866880
author Sicras-Mainar, Antoni
Tornero-Tornero, Juan Carlos
Vargas-Negrín, Francisco
Lizarraga, Isabel
Sicras-Navarro, Aram
Rejas-Gutierrez, Javier
author_facet Sicras-Mainar, Antoni
Tornero-Tornero, Juan Carlos
Vargas-Negrín, Francisco
Lizarraga, Isabel
Sicras-Navarro, Aram
Rejas-Gutierrez, Javier
author_sort Sicras-Mainar, Antoni
collection PubMed
description PURPOSE: To estimate the number of sick leave days and productivity costs in active workers with osteoarthritis (OA) who initiated opioid treatment for moderate/severe chronic pain in clinical practice in Spain. PATIENTS AND METHODS: This is a secondary analysis of the longitudinal, retrospective OPIOIDS study, using electronic medical records (EMR) of patients aged ≥18 years, who started an opioid treatment for moderate/severe chronic OA pain between 2010 and 2015 after treatment failure with ≥1 first-line drugs (acetaminophen, metamizole and/or nonsteroidal anti-inflammatory drugs [NSAIDs]). The number of days of sick leave and productivity costs were analyzed during a follow-up period of 36 months. RESULTS: A total of 5089 patients with moderate/severe chronic OA pain, aged 56.8 years (standard deviation [SD]: 4.6) (56.6% were female), were analyzed: 73.3% of them started a treatment with weak opioids and 26.7% of them were treated with strong opioids. At 36 months, adherence was 21.0% (strong opioids: 15.4%; weak opioids: 23.0%; p<0.001), and 77% of patients had at least one sick leave related with chronic OA pain, with an average of 93 days off work in all working patients (120.5 days in patients with sick leaves). Besides, 16.9% of the study population had sick leave periods that lasted at least 6 months. Pain reduction was modest (−1.2 points; −4.0%, p<0.001). The cost of sick leave was €2594 patient/year, and factors such as older age (β=0.043), female sex (β=0.036), comorbidities (β=0.035) and strong opioid use (β=0.031) were associated with higher productivity costs (p<0.05 in all associations). CONCLUSION: Active workers who started opioid treatment for moderate/severe chronic OA pain showed an increased frequency of sick leave and productivity cost, with a modest effect on pain relief. Older age, female sex, comorbidities, and strong opioids were associated with higher costs for society.
format Online
Article
Text
id pubmed-8937618
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89376182022-03-22 Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study Sicras-Mainar, Antoni Tornero-Tornero, Juan Carlos Vargas-Negrín, Francisco Lizarraga, Isabel Sicras-Navarro, Aram Rejas-Gutierrez, Javier Open Access Rheumatol Original Research PURPOSE: To estimate the number of sick leave days and productivity costs in active workers with osteoarthritis (OA) who initiated opioid treatment for moderate/severe chronic pain in clinical practice in Spain. PATIENTS AND METHODS: This is a secondary analysis of the longitudinal, retrospective OPIOIDS study, using electronic medical records (EMR) of patients aged ≥18 years, who started an opioid treatment for moderate/severe chronic OA pain between 2010 and 2015 after treatment failure with ≥1 first-line drugs (acetaminophen, metamizole and/or nonsteroidal anti-inflammatory drugs [NSAIDs]). The number of days of sick leave and productivity costs were analyzed during a follow-up period of 36 months. RESULTS: A total of 5089 patients with moderate/severe chronic OA pain, aged 56.8 years (standard deviation [SD]: 4.6) (56.6% were female), were analyzed: 73.3% of them started a treatment with weak opioids and 26.7% of them were treated with strong opioids. At 36 months, adherence was 21.0% (strong opioids: 15.4%; weak opioids: 23.0%; p<0.001), and 77% of patients had at least one sick leave related with chronic OA pain, with an average of 93 days off work in all working patients (120.5 days in patients with sick leaves). Besides, 16.9% of the study population had sick leave periods that lasted at least 6 months. Pain reduction was modest (−1.2 points; −4.0%, p<0.001). The cost of sick leave was €2594 patient/year, and factors such as older age (β=0.043), female sex (β=0.036), comorbidities (β=0.035) and strong opioid use (β=0.031) were associated with higher productivity costs (p<0.05 in all associations). CONCLUSION: Active workers who started opioid treatment for moderate/severe chronic OA pain showed an increased frequency of sick leave and productivity cost, with a modest effect on pain relief. Older age, female sex, comorbidities, and strong opioids were associated with higher costs for society. Dove 2022-03-15 /pmc/articles/PMC8937618/ /pubmed/35321217 http://dx.doi.org/10.2147/OARRR.S346746 Text en © 2022 Sicras-Mainar et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sicras-Mainar, Antoni
Tornero-Tornero, Juan Carlos
Vargas-Negrín, Francisco
Lizarraga, Isabel
Sicras-Navarro, Aram
Rejas-Gutierrez, Javier
Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_full Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_fullStr Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_full_unstemmed Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_short Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_sort sick leave and costs in active workers with chronic osteoarthritis pain in spain: outcomes of the opioids real world study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8937618/
https://www.ncbi.nlm.nih.gov/pubmed/35321217
http://dx.doi.org/10.2147/OARRR.S346746
work_keys_str_mv AT sicrasmainarantoni sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT tornerotornerojuancarlos sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT vargasnegrinfrancisco sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT lizarragaisabel sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT sicrasnavarroaram sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT rejasgutierrezjavier sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy